Gareth Morgan Investments Limited Partnership decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,385 shares of the medical research company’s stock after selling 3,513 shares during the period. Gareth Morgan Investments Limited Partnership’s holdings in Amgen were worth $4,165,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the stock. Fulton Bank N.A. increased its stake in shares of Amgen by 12.0% in the first quarter. Fulton Bank N.A. now owns 10,793 shares of the medical research company’s stock valued at $1,771,000 after buying an additional 1,158 shares during the period. Manning & Napier Advisors LLC boosted its position in Amgen by 4.8% in the first quarter. Manning & Napier Advisors LLC now owns 74,381 shares of the medical research company’s stock valued at $12,202,000 after buying an additional 3,378 shares in the last quarter. CENTRAL TRUST Co boosted its position in Amgen by 1.2% in the first quarter. CENTRAL TRUST Co now owns 56,883 shares of the medical research company’s stock valued at $9,333,000 after buying an additional 699 shares in the last quarter. Rathbone Brothers plc boosted its position in Amgen by 2.9% in the first quarter. Rathbone Brothers plc now owns 41,341 shares of the medical research company’s stock valued at $6,783,000 after buying an additional 1,169 shares in the last quarter. Finally, Burns J W & Co. Inc. NY boosted its position in Amgen by 24.0% in the first quarter. Burns J W & Co. Inc. NY now owns 14,346 shares of the medical research company’s stock valued at $2,354,000 after buying an additional 2,779 shares in the last quarter. 79.53% of the stock is currently owned by institutional investors.

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.19% during mid-day trading on Friday, reaching $169.43. The company had a trading volume of 1,571,584 shares. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The company has a market capitalization of $123.63 billion, a PE ratio of 15.43 and a beta of 1.35. The stock’s 50-day moving average price is $174.48 and its 200 day moving average price is $167.49.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. Equities analysts expect that Amgen Inc. will post $12.57 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.

ILLEGAL ACTIVITY NOTICE: “Amgen Inc. (NASDAQ:AMGN) Position Cut by Gareth Morgan Investments Limited Partnership” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/08/13/amgen-inc-nasdaqamgn-position-cut-by-gareth-morgan-investments-limited-partnership.html.

Several equities analysts have issued reports on the stock. BMO Capital Markets cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price on the stock. in a research note on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a research note on Monday, May 22nd. Leerink Swann restated a “market perform” rating and set a $161.00 target price on shares of Amgen in a research note on Thursday, June 22nd. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the company a “hold” rating in a research note on Friday, July 14th. Finally, Cowen and Company restated an “outperform” rating and set a $209.00 target price on shares of Amgen in a research note on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $186.64.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.